Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SAXAGLIPTIN MONOHYDRATE CRS (130 MG)

SAXAGLIPTIN MONOHYDRATE CRS (130 MG)

ND

DISCOVER
AMYLMETACRESOL FOR PEAK IDENTIFICATION A CRS (10 MG)

AMYLMETACRESOL FOR PEAK IDENTIFICATION A CRS (10 MG)

ND

DISCOVER
MIRABEGRON CRS (120 MG)

MIRABEGRON CRS (120 MG)

ND

DISCOVER
MIRABEGRON RACEMATE CRS (10 MG)

MIRABEGRON RACEMATE CRS (10 MG)

ND

DISCOVER
MIRABEGRON IMPURITY B CRS (10MG)

MIRABEGRON IMPURITY B CRS (10MG)

ND

DISCOVER
THIOPENTAL FOR ID AND ASSAY CRS (500 MG)

THIOPENTAL FOR ID AND ASSAY CRS (500 MG)

ND

DISCOVER
MIRABEGRON IMPURITY C CRS (10MG)

MIRABEGRON IMPURITY C CRS (10MG)

ND

DISCOVER
YOHIMBINE FOR SYSTEM SUITABILITY CRS (15 MG)

YOHIMBINE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
MIRABEGRON IMPURITY F CRS (15MG)

MIRABEGRON IMPURITY F CRS (15MG)

ND

DISCOVER
MIRABEGRON IMPURITY G CRS (15MG)

MIRABEGRON IMPURITY G CRS (15MG)

ND

DISCOVER
CALCIUM ASCORBATE DIHYDRATE CRS (15 MG)

CALCIUM ASCORBATE DIHYDRATE CRS (15 MG)

ND

DISCOVER
MARBOFLOXACIN IMPURITY MIXTURE A CRS (0.008 MG)

MARBOFLOXACIN IMPURITY MIXTURE A CRS (0.008 MG)

ND

DISCOVER